AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE
批准号:
6125206
负责人:
E Premkumar Reddy
金额:
$21.22万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 2002-11-30
关键词:
animal genetic material tag antisense nucleic acid apoptosis cell differentiation developmental genetics enzyme activity enzyme induction /repression enzyme inhibitors etoposide genetic regulatory element granulocyte immunogenetics methotrexate mitomycin C posttranslational modifications protein tyrosine kinase tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from the Applicant's Abstract) To study the nature of
genes that are induced during the apoptotic death of myeloid pre-cursor
cells, the investigators utilized 32Dcl3 cell line, which is derived from
normal mouse bone marrow and is non-tumorigenic and diploid. These cells
are strictly dependent on IL-3 for growth and apoptosis when deprived of
IL-3 from the medium. In the search for genes that are induced during
terminal differentiation of 32Dcl3 cells, the investigators identified a
novel gene termed AATYK (Apoptosis Associated Tyrosine Kinase), whose
expression is dramatically upregulated during IL-3 deprivation. The
expression of this gene, which codes for a protein with a tyrosine kinase
domain at the N-terminal end and a proline-rich domain at the C-terminal
end, is blocked in transformed myeloid cells which are deficient in
undergoing apoptosis. The experiments proposed are aimed at understanding
the role of AATYK in the apoptosis, differentiation, and transformation of
myeloid cells. The aims are: 1) [a] to test whether other apoptotic
stimuli produced by different xenobiotic agents such as calphostin C,
methotrexate etoposide, and mitomycin C result in the induction of AATYK,
[b] to test whether ectopic over-expression of AATYK renders v-abl and
bcr-abl-transformed 32D cells more sensitive to apoptotic death induced by
the above xenobiotic agents, and [c] to test whether transgenic expression
of AATYK in the v-abl or bcr-abl transformed 32D cells over-rides the block
to G-CSF-induced terminal differentiation; 2) to study the effects of
transgenic expression of AATYK on 32Dcl3 cell growth, differentiation, and
apoptosis and to determine as to how myeloid cell differentiation (in the
presence of GCSF) or apoptosis (in the absence of IL-3) is affected when
AATYK expression is inhibited using anti-sense vectors; 3) to carry out a
detailed biochemical characterization of the protein encoded by AATYK to
determine its potential tyrosine kinase activity, post-translational
modification patterns, subcellular localization and mechanism of action;
and, 4) to carry out a detailed analysis of the promoter/enhancer region of
AATYK to examine the sequence elements that play a crucial role in the
transcriptional regulation of this gene.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting FL3 and SRC kinases for AML therapy
-
批准号:10658259
-
项目类别:
-
资助金额:$23.7万
-
财政年份:2023
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
-
批准号:10671005
-
项目类别:
-
资助金额:$51.47万
-
财政年份:2020
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
-
批准号:10199970
-
项目类别:
-
资助金额:$52.52万
-
财政年份:2020
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
-
批准号:10029076
-
项目类别:
-
资助金额:$52.52万
-
财政年份:2020
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
-
批准号:10457279
-
项目类别:
-
资助金额:$51.47万
-
财政年份:2020
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting CDK4 in TGS-B Inactivated Gastrointestinal Cancers
-
批准号:8744873
-
项目类别:
-
资助金额:$17.08万
-
财政年份:2013
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
-
批准号:8985660
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2012
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
-
批准号:8787991
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2012
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
-
批准号:8435360
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2012
-
负责人:E Premkumar Reddy
-
依托单位:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
-
批准号:8238575
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2012
-
负责人:E Premkumar Reddy
-
依托单位:
Role of C-myb in Hematopoiesis and Cancer
-
批准号:7629613
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:E Premkumar Reddy
-
依托单位:
Role of C-myb in Hematopoiesis and Cancer
-
批准号:8110827
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2007
-
负责人:E Premkumar Reddy
-
依托单位:
Role of C-myb in Hematopoiesis and Cancer
-
批准号:7434474
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:E Premkumar Reddy
-
依托单位:
Role of C-myb in Hematopoiesis and Cancer
-
批准号:7266431
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:7342465
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:7577354
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:7046281
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:8110356
-
项目类别:
-
资助金额:$34.79万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:7756663
-
项目类别:
-
资助金额:$0.77万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
-
批准号:7162984
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2006
-
负责人:E Premkumar Reddy
-
依托单位:
海外基金